Research output

  1. Corrigendum to “Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial” [Eur J Cancer. 227 (2025) 115674] (European Journal of Cancer (2025) 227, (S0959804925004563), (10.1016/j.ejca.2025.115674))

    Research output: Contribution to journal › Comment/debate › peer-review

View all (1) »

ID: 170265